Neuraptive Therapeutics has secured an exclusive licence from Washington University in St Louis for a bioresorbable wireless electronic stimulation device designed for peripheral nerve repair.
The technology, which was developed at Washington University School of Medicine (WashU Medicine) in collaboration with Northwestern University, delivers targeted electrical pulses to damaged nerves to support regeneration.
The device is said to be fully bioresorbable and does not require a second procedure for removal, as it naturally breaks down in the body over time.
The newly licensed device will be added to Neuraptive Therapeutics’ existing portfolio, which includes NTX-001, a nerve fusion system currently being studied in a Phase III trial for surgical repair of transected peripheral nerves.
Washington University in St Louis office technology management assistant vice chancellor and managing director Nichole Mercier said: “WashU is excited to partner with an emerging company like Neuraptive to support the development of the bioresorbable platform originating from our research labs.
“This agreement enables the platform to be further developed to advance peripheral nerve repair and have patient impact.”
Neuraptive Therapeutics chairman and CEO Bob Radie said: “This deal is a meaningful step in strengthening our portfolio and offering more options for patients facing nerve injuries.
“The bioresorbable stimulator has real potential either on its own for repairing severed nerves or as a synergistic complement to our lead product candidate, NTX-001.
“We also intend to build on promising early research into the device’s ability to help speed recovery from crushed nerves.
“Overall, this technology could add a broader set of tools for surgeons and patients, aiming for better functional recovery, fewer long-term issues, and improved quality of life after these challenging injuries.”
Earlier this year, Washington University School of Medicine (WashU Medicine) researchers developed an Alzheimer’s blood test symptom prediction model that estimates when individuals may begin to show signs of the disease.
